A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology(r), the medical journal of the American Academy of Neurology. The study looked at the drug atogepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist taken by mouth.
